IONIS PHARMACEUTICALS, INC. financials

IONS CIK 0000874015

Source: EDGAR filings · Built 2026-06-02T03:19:08Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -320.03M -546.23M -331.32M -290.09M 18.84M 772.00K
EBITDA -369.24M -463.13M -340.88M -393.45M -12.35M -156.65M
Working Capital 2.21B 2.31B 2.19B 1.89B 2.10B 1.53B
Net Debt 1.71B 1.18B 1.09B 1.10B -847.13M 459.22M
Gross Margin 98.31% 98.41% 98.84% 97.60% 98.66% 98.36%
Operating Margin -40.45% -67.37% -44.91% -69.84% -3.72% -23.60%
Net Margin -40.41% -64.37% -46.50% -45.92% -3.53% -60.92%
Return on Equity (ROE) -77.98% -77.15% -94.72% -47.08% -3.71% -59.77%
Return on Assets (ROA) -10.82% -15.11% -12.25% -10.64% -1.09% -18.59%
Current Ratio 3.83× 8.47× 5.90× 7.07× 9.75× 3.56×
Debt-to-Equity 4.26× 2.42× 3.85× 2.41× 0.03× 1.15×
Effective Tax Rate -0.47% 1.34% -9.68% -4.55% 1.89% -256.55%
Cash Conversion Ratio 0.70× 1.10× 0.84× 1.02× -1.08× -0.08×
Accruals Ratio -0.03× 0.02× -0.02× 0.00× -0.02× -0.20×
SBC % of Revenue 14.19% 18.46% 13.43% 17.07% 14.89% 31.55%
CapEx Coverage -5.22× -11.06× -12.92× -17.45× 2.58× 1.02×
Free Cash Flow Per Share $-2.00 $-3.65 $-2.31 $-2.05 $0.13 $0.01

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/FCF 227.77×
FCF Yield 0.44% 0.01%
P/S 13.69× 7.83× 9.27× 9.13× 5.30× 10.88×
P/B 26.41× 9.38× 18.88× 9.37× 5.57× 10.68×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 943.71M 705.14M 787.65M 587.37M 810.46M 729.26M
Revenues 203.33M 226.58M 324.50M 151.89M 440.01M 290.28M
Cost of Goods and Services Sold 15.91M 11.21M 9.13M 14.12M 10.84M 11.95M
Research and Development Expense 915.62M 901.53M 899.63M 638.20M 531.00M
Selling, General and Administrative Expense 393.87M 267.47M 232.62M 150.29M 186.35M 354.32M
Operating Income (Loss) -381.68M -475.08M -353.73M -410.19M -30.19M -172.08M
Income Tax Expense (Benefit) 1.79M -6.17M 32.32M 11.74M -551.00K 345.19M
Net Income (Loss) Attributable to Parent -381.39M -453.90M -366.29M -269.72M -28.60M -444.26M
Earnings Per Share, Basic $-2.38 $-3.04 $-2.56 $-1.90 $-0.20 $-3.18
Weighted Average Number of Shares Outstanding, Basic 160.01M 149.51M 143.19M 141.85M 141.02M 139.61M
Earnings Per Share, Diluted $-2.38 $-3.04 $-2.56 $-1.90 $-0.20 $-3.18
Weighted Average Number of Shares Outstanding, Diluted 160.01M 149.51M 143.19M 141.85M 141.02M 139.61M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 372.26M 242.08M 399.27M 276.47M 869.19M 397.66M
Assets, Current 2.99B 2.62B 2.64B 2.20B 2.35B 2.13B
Assets 3.52B 3.00B 2.99B 2.53B 2.61B 2.39B
Long-term Debt 1.81B 1.25B 1.31B 1.19B
Liabilities, Current 781.57M 309.32M 448.09M 311.56M 240.55M 598.90M
Long-term Debt, Excluding Current Maturities 1.33B 1.20B 1.24B 1.18B
Liabilities 3.03B 2.42B 2.60B 1.96B 1.84B 1.65B
Stockholders' Equity Attributable to Parent 489.09M 588.35M 386.69M 572.89M 771.74M 743.28M
Common Stock, Shares, Outstanding 163.30M 157.91M 144.34M 142.06M 141.21M 140.37M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -268.58M -500.95M -307.51M -274.37M 30.80M 35.89M
Payments to Acquire Property, Plant, and Equipment 51.44M 45.28M 23.80M 15.72M 11.96M 35.12M
Net Cash Provided by (Used in) Investing Activities -277.78M -134.03M -214.13M -262.64M 194.91M 274.48M
Payments for Repurchase of Common Stock 0 0 90.55M
Net Cash Provided by (Used in) Financing Activities 675.84M 478.06M 644.08M -55.30M 245.93M -596.61M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (IONS CIK 0000874015), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CHRD

Chord Energy Corp

LGND

LIGAND PHARMACEUTICALS INCORPORATED

SVCO

Silvaco Group, Inc.